{"contentid": 488168, "importid": NaN, "name": "Data offer further evidence on Akili\u00e2\u0080\u0099s digital therapeutic in ADHD", "introduction": "Akili Interactive has announced the publication of full data from a multi-site open-label study (STARS Adjunct) evaluating the impact of the digital therapeutic EndeavorRx on symptoms and functional impairments in children with attention-deficit/hyperactivity disorder (ADHD).", "content": "<p>Akili Interactive has announced the publication of full data from a multi-site open-label study (STARS Adjunct) evaluating the impact of the digital therapeutic EndeavorRx on symptoms and functional impairments in children with attention-deficit/hyperactivity disorder (ADHD).</p>\n<p>These results, which have been published in the journal Nature Digital Medicine, demonstrate statistically-significant improvement in all predetermined endpoints of the study including parent and clinician ratings of children&rsquo;s ADHD symptoms and related impairments in daily life.</p>\n<p>The STARS Adjunct study data, along with results from four other clinical studies of EndeavorRx in pediatric ADHD, were presented to the US Food and Drug Administration and were part of the data package that led to FDA clearance of EndeavorRx in June 2020.</p>\n<p>Anil Jina, chief medical officer of Akili, which is part of London-listed biotech PureTech Health (LSE: PRTC),&nbsp;said: &ldquo;The results of this study highlight the impact EndeavorRx can have on patients&rsquo; day-to-day lives and show the potential benefits of incorporating digital therapeutics into multifaceted treatment plans, including those with traditional pharmacological interventions.&rdquo;</p>\n<p>Scott Kollins, professor of psychiatry and director of the ADHD program at the Duke University School of Medicine, faculty member at the Duke Clinical Research Institute and lead author of the publication, added: &ldquo;The findings from this latest study offer additional information about the effectiveness of EndeavorRx in children treated with front-line pharmacotherapy for ADHD.</p>\n<p>&ldquo;As a clinician who works with children with ADHD, I am happy to see these results from an innovative treatment that can improve both symptoms and impairments in children with ADHD.&rdquo;</p>", "date": "2021-03-26 16:49:00", "meta_title": NaN, "meta_keywords": NaN, "meta_description": NaN, "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-26 16:30:11", "updated": "2021-03-26 17:15:00", "access": NaN, "url": "https://www.thepharmaletter.com/article/data-offer-further-evidence-on-akili-s-digital-therapeutic-in-adhd", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "akili_large.png", "image2id": "akili_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": "ADHD", "sector_tag": "Biotechnology", "therapy area_tag": "CNS Diseases, Neurological", "topic_tag": "Drug Trial, Research", "geography_tag": "USA", "company_tag": "Akili Interactive, PureTech Health", "drug_tag": "EndeavorRx", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-26 16:49:00"}